<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02839941</url>
  </required_header>
  <id_info>
    <org_study_id>KT-2016-1</org_study_id>
    <nct_id>NCT02839941</nct_id>
  </id_info>
  <brief_title>Iguratimod in Kidney Transplant Recepients</brief_title>
  <official_title>An Open-label Study to Evaluate the Effect of Iguratimod Concomitant With Conventional Immunosuppressive Drugs on Preventing Antibody-induced Rejection in Human Leukocyte Antigen(HLA) Highly Mismatched Kidney Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the effect of iguratimod concomitant with
      conventional immunosuppressive drugs on preventing antibody-induced rejection in HLA Highly
      mismatched Kidney Transplant recipients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biopsy-proven acute rejection rates</measure>
    <time_frame>0-52 week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival of transplanted kidney</measure>
    <time_frame>52 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Donor Specific Antibody(DSA) level compared to baseline</measure>
    <time_frame>52 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft renal function</measure>
    <time_frame>52 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>0-52 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>experiment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iguratimod</intervention_name>
    <description>Subjects will receive iguratimod orally, twice a day, for consecutive 52 weeks</description>
    <arm_group_label>experiment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>All subjects will receive mycophenolate mofetil for consecutive 52 weeks</description>
    <arm_group_label>experiment</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>All subjects will receive tacrolimus for consecutive 52 weeks</description>
    <arm_group_label>experiment</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <description>All subjects will receive glucocorticoids for consecutive 52 weeks</description>
    <arm_group_label>experiment</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged ≥18, &lt;65 years

          -  At least 2 weeks post kidney transplantation from deceased or living donor

          -  Stable renal graft function, i.e., serum creatinine undulation for 3 consecutive test
             &lt;±10%

          -  Serum creatinine&lt;1.5×upper limits of normal(ULN)

          -  Number of HLA mismatches ≥ 4

          -  Panel Reactive Antibody(PRA) value pre-transplantation &lt;10%

          -  Concentration of conventional immunosuppressive drugs reach target ranges

          -  Subjects are willing to participate in the study, fully informed, and sign informed
             consent form(ICF)

          -  Women of childbearing potential (WOCBP) must have a negative pregnancy test within 24
             hours prior to the start of study medication, and agree to use an acceptable method to
             avoid pregnancy for the entire study period and for up to 3 months after the last dose
             of study medication.

        Exclusion Criteria:

          -  Pregnant or nursing women

          -  Currently clinical acute rejection;

          -  Graft function hasn't recovered for delayed graft function (DGF), or primary
             non-function (PNF)

          -  Second or subsequent kidney transplant or multi-organ recipients (e.g. kidney and
             pancreas)

          -  Subjects with Liver failure

          -  Abnormal hepatic, renal and hematopoietic function,

               1. Alanine transaminase(ALT), Aspartate transaminase(AST)&gt;1.5×ULN

               2. White blood cell(WBC)&lt;3.5×10^9/L

               3. Hemoglobin(HGB)&lt;80 g/L

               4. Platelet count(PLT)&lt;80×10^9/L.

          -  Severe clinically relevant disease,

               1. Abnormality in chest X ray image, such as Tuberculosis, Pulmonary interstitial
                  fibrosis, or symptom or physical sign of clinical significance

               2. Serious cardiovascular, hepatic, hematological, endocrinal disease, or malignancy
                  3）History of serious cardiovascular, hepatic, hematological, endocrinal disease,
                  or malignancy

             4) Immunodeficiency, uncontrolled active infection, and active gastrointestinal
             disease.

          -  Women or men of childbearing potential plan to be pregnant recently;

          -  Allergic with study drug, or excipient

          -  Subject with psychiatric illness, which may put him/her into unacceptable risk in the
             opinion of investigators

          -  Has received or is receiving Rituximab treatment

          -  Iguratimod treatment within 1 week pre-transplantation, or during screening period

          -  Received live vaccines in the previous 3 months, or plan to receive live vaccines
             during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Gu</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hao Chen</last_name>
    <email>chenhao_nju@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2016</study_first_submitted>
  <study_first_submitted_qc>July 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2016</study_first_posted>
  <last_update_submitted>November 30, 2016</last_update_submitted>
  <last_update_submitted_qc>November 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

